David C. Hastings

David Hastings has a strong background in finance and leadership roles within the biopharmaceutical industry. David joined Arbutus Biopharma Corporation in 2018 as the Chief Financial Officer, where they currently hold the role. Prior to this, they served as the Director and Audit Committee Chair at SCYNEXIS, Inc. starting in 2015. In 2018, they also became the Director and Audit Committee Chair at VBL Therapeutics. Before that, they were the CFO of Unilife Corporation from 2015 to 2017, and the CFO of Incyte from 2003 to 2014. David also held the position of CFO and Treasurer at ArQule from 2000 to 2003. David's experience in finance and leadership began at Coopers & Lybrand (now PricewaterhouseCoopers) where they worked as a Senior Manager from 1985 to 1994.

David Hastings obtained a Bachelor's degree in Economics from the University of Vermont between 1981 and 1983. Prior to that, they attended Denison University from 1979 to 1981. No degree or field of study is provided for this period.